CMS Rethinks Common Biosimilar Billing Codes In Response To Rx Makers

In response to drug makers, CMS is considering undoing the policy of putting biosimilars that reference the same brand biologic in common billing codes, even though congressional Medicare advisers recommend that the agency use the policy more aggressively by grouping pay of both brands and biosimilars. The Obama administration instituted the policy to get biosimilars makers to compete on price, and CMS expects to soon group payment of two biosimilars for the first time. The Physician Fee Schedule rule that...